Progyny, Inc. (PGNY) Current Ratio
- Current ratio · latest quarter: Value 2.14×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.14× | Current assets / current liabilities. $513.02M ÷ $240.08M ≈ 2.14× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 513.02M USD | Assets, Current |
| Current obligations | 240.08M USD | Liabilities, Current |
| Cash and equivalents | 152.63M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 84.29M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 257.48M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 152.05M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $513.02M | $240.08M | $152.63M | $84.29M | $257.48M | (m) | $152.05M | (m) | 2.14× |
| 2026-03-31 | $501.55M | $235.74M | $131.61M | $93.50M | $263.61M | (m) | $157.83M | (m) | 2.13× |
| 2025-12-31 | $551.77M | $202.39M | $112.24M | $197.86M | $220.29M | (m) | $124.07M | (m) | 2.73× |
| 2025-09-30 | $622.01M | $210.49M | $133.98M | $211.22M | $252.50M | (m) | $123.09M | (m) | 2.96× |
| 2025-06-30 | $594.40M | $220.42M | $132.51M | $172.59M | $271.85M | (m) | $140.52M | (m) | 2.70× |
| 2025-03-31 | $567.69M | $237.13M | $109.24M | $146.88M | $299.74M | (m) | $145.71M | (m) | 2.39× |
| 2024-12-31 | $472.72M | $168.63M | $162.31M | $65.64M | $235.32M | (m) | $95.10M | (m) | 2.80× |
| 2024-09-30 | $546.30M | $208.47M | $91.48M | $144.24M | $280.72M | (m) | $130.46M | (m) | 2.62× |
| 2024-06-30 | $582.24M | $225.38M | $94.96M | $167.23M | $293.80M | (m) | $151.75M | (m) | 2.58× |
| 2024-03-31 | $681.51M | $205.92M | $114.96M | $256.87M | $297.21M | (m) | $130.17M | (m) | 3.31× |
| 2023-12-31 | $640.41M | $185.95M | $97.30M | $273.79M | $241.87M | (m) | $125.43M | (m) | 3.44× |
| 2023-09-30 | $611.27M | $193.42M | $158.07M | $177.48M | $268.77M | (m) | $132.04M | (m) | 3.16× |
| 2023-06-30 | $561.13M | $193.90M | $170.57M | $111.92M | $264.96M | (m) | $130.16M | (m) | 2.89× |
| 2023-03-31 | $527.08M | $206.87M | $155.32M | $52.57M | $313.25M | (m) | $145.62M | (m) | 2.55× |
| 2022-12-31 | $433.86M | $159.54M | $120.08M | $69.22M | $240.07M | (m) | $109.29M | (m) | 2.72× |
| 2022-09-30 | $401.87M | $156.87M | $72.52M | $68.47M | $258.04M | (m) | $104.16M | (m) | 2.56× |
| 2022-06-30 | $356.38M | $144.90M | $54.73M | $67.66M | $229.86M | (m) | $92.66M | (m) | 2.46× |
| 2022-03-31 | $309.03M | $128.72M | $38.82M | $66.86M | $198.12M | (m) | $84.68M | (m) | 2.40× |
| 2021-12-31 | $258.54M | $98.82M | $91.41M | $28.00M | $134.56M | (m) | $61.40M | (m) | 2.62× |
| 2021-09-30 | $254.42M | $104.48M | $92.22M | $22.09M | $135.18M | (m) | $55.42M | (m) | 2.44× |
| 2021-06-30 | $238.49M | $98.78M | $48.75M | $45.22M | $140.77M | (m) | $54.68M | (m) | 2.41× |
| 2021-03-31 | $227.80M | $101.00M | $29.82M | $77.09M | $116.67M | (m) | $57.31M | (m) | 2.26× |
| 2020-12-31 | $190.22M | $77.79M | $70.31M | $38.99M | $75.66M | (m) | $43.51M | (m) | 2.45× |
| 2020-09-30 | $184.59M | $74.17M | $53.97M | $50.99M | $78.30M | (m) | $42.21M | (m) | 2.49× |
| 2020-06-30 | $159.71M | $57.67M | $49.39M | $41.98M | $65.00M | (m) | $31.93M | (m) | 2.77× |
| 2020-03-31 | $161.94M | $59.06M | $91.63M | (m) | $65.86M | (m) | $39.44M | (m) | 2.74× |
| 2019-12-31 | $132.44M | $36.16M | $80.38M | (m) | $47.06M | (m) | $19.39M | (m) | 3.66× |
| 2019-09-30 | $53.34M | $57.56M | $7.66M | (m) | $44.34M | (m) | $23.48M | (m) | 0.93× |
| 2018-12-31 | $24.54M | $30.20M | $127.00K | (m) | $23.32M | (m) | $15.58M | (m) | 0.81× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |